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The goal of the study was to determine baseline protective titers of antibodies to Streptococcus pneumoniae surface protein A
(PspA) and capsular polysaccharide in individuals with and individuals without type 2 diabetes mellitus. A total of 561 individu-
als (131 individuals with diabetes and 491 without) were screened for antibodies to PspA using a standard enzyme-linked immu-
nosorbent assay (ELISA). A subset of participants with antibodies to PspA were retested using a WHO ELISA to determine titers
of antibodies to capsular polysaccharide (CPS) (serotypes 4, 6B, 9V, 14, 18C, 19A, 19F, and 23F). Functional activity of antibodies
was measured by assessing their ability to enhance complement (C3) deposition on pneumococci and promote killing of op-
sonized pneumococci. Titers of antibodies to protein antigens (PspA) were significantly lower in individuals with diabetes than
controls without diabetes (P  0.01), and antibodies showed a significantly reduced complement deposition ability (P  0.02).
Both antibody titers and complement deposition were negatively associated with hyperglycemia. Conversely, titers of antibodies
to capsular polysaccharides were either comparable between the two groups or were significantly higher in individuals with dia-
betes, as was observed for CPS 14 (P  0.05). The plasma specimens from individuals with diabetes also demonstrated a higher
opsonophagocytic index against CPS serotype 14. Although we demonstrate comparable protective titers of antibodies to CPS in
individuals with and individuals without diabetes, those with diabetes had lower PspA titers and poor opsonic activity strongly
associated with hyperglycemia. These results suggest a link between diabetes and impairment of antibody response.
Streptococcus pneumoniae is an important human pathogen,causing each year an estimated 40,000 deaths in the United
States alone and 1 million globally. Infections caused by S. pneu-
moniae can range from mild infections, such as otitis media and
sinusitis, to severe and fatal infections, such as pneumonia and
meningitis (19). S. pneumoniae mainly causes infections in chil-
dren, the elderly, and immunocompromised individuals (6, 11).
However, elderly individuals with comorbidities such as cardio-
vascular disease and diabetes are at greater risk of developing se-
vere invasive infections, which are often fatal (23).
The prevalence and incidence of type 2 diabetes mellitus have
increased at an alarming rate, and currently, more than 20 million
people in the United States have been diagnosed with diabetes.
This number is expected to increase to 39 million by 2050. Diabe-
tes has been implicated as the single greatest risk factor for pneu-
mococcal bacteremia in individuals under the age of 40 (odds
ratio [OR], 4.2; 95% CI confidence interval [CI], 1.1 to 16.7) (21,
22) and among those with no other documented comorbidities
(OR, 2.3; 95% CI, 1.3 to 3.9) (46). According to one study, the risk
of community-acquired pneumococcal pneumonia was 1.5-fold
higher in individuals with diabetes than nondiabetes controls
(45). Infections in individuals with diabetes occurs with greater
severity and are associated with an increased risk of complications
(4, 38). The increased susceptibility to infections in individuals
with diabetes has been reported to be due in part to defects in both
adaptive and cell-mediated immunity. Several immune defects
have been noted in individuals with diabetes, particularly poorly
controlled diabetes. Poor glucose control impairs a range of neu-
trophil and macrophage functions, such as chemotaxis, adher-
ence, phagocytosis, and intracellular killing of microorganisms (8,
37). Additionally, decreases in mitogen-stimulated lymphocyte
proliferation and defects in T-cell, B-cell, and dendritic cell func-
tions have also been described in individuals with diabetes (12).
Protection against pneumococcal carriage and invasive infec-
tions is complex and multifactorial and has been shown to involve
both antibody-dependent and independent mechanisms. Anti-
body-mediated protection is mainly dependent on capsular type-
specific and anti-S. pneumoniae surface protein A (anti-PspA) an-
tibodies, which develop as a result of either asymptomatic carriage
or infection, resulting in protection against future infections (17,
30). The mechanism of protection is characterized by antibody-
mediated enhancement of complement deposition followed by
clearance of pneumococci via opsonophagocytosis by neutrophils
(41). A critical role of CD4 T cells in antibody-independent im-
munity to carriage has recently been described, where coloniza-
tion of the lungs and nasopharyngeal cavity resulted in activation
and infiltration of CD4 T cells, in particular, Th17 cells. Activa-
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tion of Th17 resulted in synthesis and release of the effector cyto-
kine interleukin-17, recruitment of neutrophils, and phagocytic
killing of pneumococci (2, 29, 31).
Several studies have evaluated immune responses to natural
exposure and vaccination in individuals with and individuals
without diabetes (3, 27). Results of studies evaluating immune
responses to vaccines and vaccine efficacy are highly variable.
Measurement of antibody titers after pneumococcal vaccination
indicated that antibody titers in individuals with and individuals
without diabetes were comparable in magnitude (27); however,
patients with diabetes showed a delayed response to immuniza-
tion (44) and impairments in production of circulating B cells and
specific IgM in response to vaccination. These impairments were
attributed to abnormalities in T-cell function. Contrary to these
immune impairments, the overall efficacy of vaccine was reported
to be between 56 and 70% (5, 15, 44), which is similar to what has
been reported (65 to 81%) for those without diabetes (20, 33, 34,
43). These discrepancies can be explained by the fact that studies
determining vaccine efficacy were largely performed using a het-
erogeneous group of at-risk participants, including those with di-
abetes. As a result, these trials provide limited information on
vaccine efficacy specific for individuals with diabetes. Further-
more, owing to the short-term efficacy of unconjugated polysac-
charide (PS) vaccine, revaccination is recommended in both
healthy controls and high-risk groups. Measurement of efficacy
within the first 5 years of administration suggested that unconju-
gated polysaccharide vaccine was 75% effective in preventing in-
vasive pneumococcal disease in immunocompetent individuals
aged 65 years and above. The efficacy was reduced to 37% the first
year, 18% every 5 years for 10 years, and 0% thereafter. However,
revaccination in immunocompetent adults resulted in a signifi-
cant increase in serotype-specific anticapsular IgG antibody and
subsequent long-lasting protection against pneumonia and inva-
sive pneumococcal disease (18). Given these findings, it is reason-
able to hypothesize that antibodies generated in individuals with
diabetes, even though they are similar in titer to those in nondia-
betic individuals, are functionally impaired. We therefore de-
signed this study to (i) determine the baseline titer of antibodies to
pneumococcal surface protein A and capsular polysaccharide in
individuals with and individuals without diabetes and (ii) deter-
mine if antibodies in these individuals are functionally compara-
ble to those in individuals without diabetes.
MATERIALS AND METHODS
Subjects. The study was approved by the University of Texas Health Sci-
ence Center at Houston Institutional Review Board (IRB) and the Com-
mittee for Protection of Human Subjects (CPHS). This study was con-
ducted using stored plasma from 561 recently recruited participants from
the Cameron County Hispanic Cohort (CCHC). The CCHC is a commu-
nity-based cohort in Cameron County, TX, comprised of 2,500 randomly
selected Hispanic participants from the U.S.-Mexico border region (20).
The rate of diabetes among CCHC participants is 17.9%, using the 2006
American Diabetes Association (ADA) diagnostic criteria for diabetes
(1a). However, if we use the 2010 ADA revised diagnostic criteria, which
adds a level of glycated hemoglobin (A1c) of over 6.5% to the original
criteria, the prevalence rises to 30.7%, twice the reported national rates of
diabetes among all Americans and nearly twice as high as that previously
established rates among Mexican Americans (1, 14). Plasma was obtained
from consenting participants on enrollment into the CCHC and were
kept frozen as described previously (14). Variables of interest for this
study that were collected during enrollment in the CCHC include age,
body mass index (BMI), fasting blood glucose (FBG) levels, and A1c levels.
Clinical chemistries were performed in a Clinical Laboratory Improvement
Amendments-approved laboratory as described previously (3).
For the purposes of this study, individuals with diabetes were defined
on the basis of the original 2006 American Diabetes Association criteria
(1a). This includes participants with a diagnosis of diabetes who were also
on medication for diabetes or those with fasting blood glucose levels
of 126 mg/dl. Those with fasting blood glucose values of 126 mg/dl
and no history of diabetes or receipt of diabetes medication were classified
as not having diabetes. From our study samples, 132 individuals were
identified to have diabetes and 429 were identified to not have diabetes.
Among the 132 participants with diabetes, only 89 were on medication,
whereas 43 were not on any hypoglycemic medication. To determine the
overall health status of participants, we collected data on antibiotic usage
and hospitalization at the time of enrollment and blood draw. Of the 561
participants, only 5 were on antibiotics and none reported hospitalization
3 months prior to the enrollment. We also compared the values of albu-
min between those with and those without diabetes and found no signif-
icant difference between the groups. Only one participant in the diabetes
group (n  132) reported being on dialysis, whereas the rest did not report
any renal impairment.
Measurement of serum concentration of antibodies to PspA. Anti-
bodies to PspA were measured using standard enzyme-linked immu-
nosorbent assay (ELISA) methods (39, 47). We used stored plasma sam-
ples instead of serum samples. Serum is the most desirable specimen for
measuring antibody titer; however, both plasma and serum specimens
have been used interchangeably for measurement of antibodies in pneu-
mococcal infections, and reported titers were observed to be comparable
in both specimens (2, 15a) (Elizen kits; ZenTech). Ninety-six-well ELISA
plates were coated with 1 g/ml of either a recombinant 30-kDa N-ter-
minal fragment of family 1 PspA, 10 g/ml of a smaller (13-kDa) internal
fragment of PspA containing proline repeats (proline-rich region [PRR])
(9), or the recombinant Staphylococcus aureus Efb (28) protein in bicar-
bonate buffer (50 ml 0.06 M Na2HCO3, 40 ml 0.06 M Na2CO3, 10 ml
deionized H2O, pH 9.6). The proline-rich region was used since it is highly
conserved in all PspA isoforms and is known to be immunogenic (9).
Plates were coated at 4°C overnight, followed by blocking for 1 h at room
temperature using phosphate-buffered saline (PBS; pH 7.4; Gibco Invit-
rogen, MO) containing 1% bovine serum albumin (BSA; Sigma-Aldrich,
CA). Plates coated with 1 g/ml of BSA only were used as a negative
control to account for nonspecific binding of serum proteins to BSA.
Pooled human serum with a known titer of total IgG to PspA (1.85 mg/ml;
a kind gift from David Briles, University of Alabama at Birmingham) was
used as the standard for determining the concentration of total IgG to
PspA in unknown serum samples. Pooled serum was used at a starting
dilution of 1:1,000 in PBS–1% BSA (which corresponds to 1.8 g/ml of
IgG to PspA) and titrated 1:3, in duplicate. Controls were included in each
plate to account for nonspecific binding. Plasma samples were diluted
1:30 in PBS–1% BSA. Plates were incubated at 37°C for 1.5 h and washed
3 times with PBS containing 0.05% Tween 20 (PBST), followed by addi-
tion of 100 l of goat anti-human alkaline phosphatase (AP)-conjugated
secondary antibody (Southern Biotech). Plates were incubated for an ad-
ditional hour at room temperature, before they were washed 3 times with
PBST and developed using 100 l of p-nitrophenylphosphate (pNpp; Sig-
ma-Aldrich, CA). The absorbance was read at 450 nm with a preread
setting (SpectraMax M5 microplate reader [Molecular Devices] with Soft-
Max Pro software [version 4.8]). Analysis was repeated to ensure accu-
racy. A positive IgG outcome was set at an optical density (OD) reading of
0.25, corresponding to an IgG titer of 150 ng/ml.
Antibody-mediated complement deposition on pneumococcal sur-
face. To determine if antibodies measured by ELISA are functionally ac-
tive, we measured their ability to deposit complement on the surface of
pneumococci. Plasma specimens with an antibody titer of 150 ng/ml
were selected from both diabetic and nondiabetic participants for use in a
complement deposition assay. A capsule type 2 strain of S. pneumoniae
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(strain D39) was used for measurement of complement factor C3 depo-
sition. An isogenic mutant of capsule type 2 strains (mutant Tre 121.13)
was used as a positive control. This strain is deficient in surface expression
of both PspA and PspC, the two proteins known to prevent complement
activation and deposition on pneumococci (10, 40). This mutant is there-
fore susceptible to complement deposition by the classical and alternative
pathways, and complement becomes deposited at significantly elevated
levels even in the absence of antibodies. Both strains were cultured to an
OD at 600 nm of 0.4 (corresponding to approximately 4  108 CFU/ml)
in Todd-Hewitt–5% yeast extract (THY) broth at 37°C. An aliquot of
culture corresponding to 1  106 CFU/ml was spun to pellet bacteria,
followed by resuspension of the pellet into either 100 l of Hanks bal-
anced salt solution with 0.1% gelatin (HBSSG; negative controls) or 10%
heat-inactivated human plasma diluted in HBSSG. Samples were incu-
bated for 30 min at 37°C, then washed with HBSSG, and centrifuged; and
the supernatants were discarded. Pellets were resuspended in 100 l of
HBSSG containing 25 g/ml of baby rabbit complement (Pel-Freez Bio-
logicals, Rogers, AK). Specimens were incubated for 30 min at 37°C, fol-
lowed by washing and resuspension into 100 l of fluorescein-conjugated
goat IgG fraction to rabbit complement C3 (MP Biomedical) diluted to a
final concentration of 1:100 in PBS–1% BSA. Samples were incubated for
30 min at 37°C, washed once to remove unbound antibody, and fixed by
resuspension in a 1:1 mixture of 2% para-formaldehyde and PBS–1%
BSA. Samples were analyzed using a BD FACS CANTO II flow cytometer
and FACSDiva software (version 6.1.1).
Measurement of serum concentration of anticapsular antibodies
using WHO ELISA. Measurement of the anticapsular IgG was performed
on a total of 64 plasma specimens that previously tested positive for anti-
PspA. Titers were measured using a 3rd-generation sandwich ELISA as
described previously (48). Briefly, plates were coated with purified capsu-
lar polysaccharides from the most common serotypes (serotypes 4, 6B,
9V, 14, 18C, 23F, and 9V) and less common serotypes (serotypes 19F and
19A). Plates were coated for 4 to 5 h at 37°C and then transferred to 4°C.
Plasma specimens to be used in the study were absorbed with 5 g/ml of
cell wall PS (Statens Serum Institute, Copenhagen, Denmark) and 10
g/ml of 22-F PS in a final volume of 1 ml of PBST for 30 min at room
temperature. Serum pool 89-SF was absorbed only with cell wall PS and
used as the standard. The preabsorbed plasma specimen and the 89-SF
serum pool were serially diluted and added to the wells of a PS-coated
plate. Plates were incubated for 2 h at room temperature and washed,
followed by addition of AP-conjugated goat anti-human IgG. Incubation
was continued at room temperature for 2 h, followed by another wash and
addition of substrate. The reaction was stopped using 3 N NaOH, and the
optical density was measured at 405 nm and 690 nm using a microplate
ELISA reader. The amount of antibody was calculated from the standard
curve made from sample 89-SF.
Multiplexed OPA. A total of 52 serum specimen were selected on the
basis of their anticapsular IgG titers and were tested against pneumococci
of eight serotypes (9V, 23F, 4, 18C, 6B, 19F, 14, and 19A) using a multi-
plexed opsonophagocytic killing assay (OPA) as described previously (7).
For selection purposes, each target bacterium is made resistant to one of
the four antibiotics (optochin, streptomycin, spectinomycin, and trim-
ethoprim) and was left sensitive to the other three. Target strains were
thawed, washed in opsonization buffer B (Hanks balanced salt solution
with Mg2 and Ca2 containing 0.1% gelatin and 5% fetal bovine serum),
and reconstituted to a final concentration of 2  105 CFU/ml. Two pools
were made by mixing equal volumes of four serotypes in each pool. To
inactivate human complement proteins, plasma specimens were heat in-
activated at 56°C for 30 min, followed by serial dilution of each sample.
Twenty microliters of diluted serum specimens was added to the wells of
96-well round-bottom plates (Corning Inc., Corning, NY) and mixed
with 10 l of the bacterial suspension, and the mixture was incubated at
room temperature on a shaker (mini-orbital shaker; Bellco Biotechnol-
ogy, Vineland, NJ) at 700 rpm for 30 min. Following incubation, 10 l of
baby rabbit complement (Pel-Freez Biologicals, Rogers, AK) and 40 l of
HL-60 cells (approximately 1  107 cells/ml) which were differentiated
into granulocytes were added and the incubation was continued in a tissue
culture incubator at 37°C (5% CO2) for 45 min with constant shaking at
700 rpm. On completion of the incubation, plates were cooled on ice for
15 min and a 10-l aliquot was spotted onto four different THY agar
plates (Todd-Hewitt broth with 0.5% yeast extract and 1.5% agar). An
equal volume of overlay agar (Todd-Hewitt broth with 0.5% yeast extract
and 0.75% agar) containing one of the four antibiotics was added to each
agar plate. After an overnight incubation at 37°C, the number of bacterial
colonies in the agar plates was enumerated. Opsonization titers were de-
fined as the plasma dilution that killed 50% of bacteria.
Statistical analysis. Univariate analyses of baseline variables found the
distributions to be nonnormal and skewed. As a result, nonparametric
alternatives were used for data analysis. Differences in median values of
baseline characteristics between individuals with and individuals without
diabetes and between those with positive IgG titers and those with nega-
tive IgG titers were compared using nonparametric Wilcoxon two-sample
tests or chi-square tests. Stratified analyses and multivariable logistic re-
gression were used to assess potential confounders or interactions. Unad-
justed and adjusted odds ratios comparing outcomes of positive or nega-
tive IgG titers were calculated using multivariable logistic regression.
Correlations were calculated using nonparametric alternatives. All analy-
ses were considered significant when P values were 0.05. All analyses
were run using SAS software (version 9.2; SAS Institute Inc., Cary, NC).
RESULTS
Participant characteristics. The analysis was performed on a total
of 561 participants (132 with diabetes and 429 without diabetes).
Participants were not specifically asked if they had previously re-
ceived a pneumococcal vaccine. This is a population in which only
11.9% has private insurance capable of financing the expensive
pneumococcal vaccine (14). It is unlikely that individuals in this
study had received the S. pneumoniae vaccine. Less than half of all
participants self-reported that they had diabetes, and only half of
the self-reported (89/132) individuals were on medication of any
kind, further reducing the probability of pneumococcal vaccina-
tion (even among the self-reported diabetes participants) (14).
Furthermore, only 5 participants out of the total of 561 in this
study were on antibiotics when the specimens were obtained. The
majority of the participants in this study were overweight or obese
(80.9%), and nearly a third of the participants met the Adult
Treatment Panel (ATP) III definition of metabolic syndrome (16).
A total of 13.6% in this subset had diabetes (14).
Median values (interquartile [IQ] ranges) were compared for
gender, age, BMI, FBG level, and glycated hemoglobin (A1c) level.
Results of comparisons are presented in Table 1. There were no
significant differences between genders; however, participants
with diabetes were significantly older than those without diabetes
(median age, 59 versus 45 years [P  0.001]). Significant differ-
ences were also observed in BMI (32.2 versus 29.9 [P  0.001]),
FBG concentration (144 versus 96 mmol/liter [P  0.001]), A1c
level (8% versus 5.97% [P  0.001]), C-reactive protein (CRP)
concentration (P  0.01), high-density lipoprotein (HDL) con-
centration, and triglyceride concentration (P  0.001).
Diabetes status is associated with lower titers of IgG to PspA
independent of age. Carriage has been shown to be a prerequisite
for invasive pneumococcal infections, and preexisting antibodies
to PspA confer protection against carriage (39). We therefore
measured anti-PspA titers in the plasma of participants with and
individuals without diabetes. Levels of antibody to the full-length
30-kDa N-terminal region of family 1 PspA were measured using
a standard ELISA method. A significantly higher titer of antibod-
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ies was observed in individuals with diabetes than in diabetic con-
trols (P  0.001) (Fig. 1). Three hundred twenty-five (57.9%) of
561 participants had a positive baseline IgG titer. A total of 43.2%
of plasma specimens from those with diabetes and 63.5% from
those without diabetes had a positive IgG titer (P  0.0001) (Table
2). The mean concentration of IgG in plasma samples of those
with diabetes was 183 ng/ml, whereas it was 227 ng/ml in those
without diabetes (P  0.01). Specimens positive for the 30-kDa
PspA antigen were screened for reactivity against the smaller in-
ternal fragment of PspA. Specimens positive for the full-length
30-kDa fragment were also positive for the smaller internal frag-
ment of PspA; however, no significant difference between titers of
individuals with diabetes and those of individuals without diabe-
tes was observed. These results suggested that the responses to the
full-length PspA protein observed were the result of specific anti-
PspA antibodies in the plasma of participants rather than cross-
reacting molecules.
To further explore the immune response to protein anti-
gens, we also measured the concentration of antibody to the S.
aureus virulence factor Efb. Our results indicated that the re-
sponse to this antigen was also significantly lower in individu-
als with diabetes (mean IgG concentration, 41 ng/ml) than
controls without diabetes (mean concentration, 51.23 ng/ml)
(P  0.01) (Fig. 1B).
Age and BMI are known to affect antibody response. We there-
fore determined the association of antibody titers with age and
BMI (Table 3). When diabetes was stratified by age, a significant
difference was observed between individuals with and individuals
without diabetes, indicating that the observed differences in titers
were the result of diabetes rather than age. Additionally, the dif-
ferences in IgG titers remained significantly different between in-
dividuals with and individuals without diabetes even after con-
trolling for BMI (P  0.001 for BMI of 30, P  0.01 for BMI of
30), suggesting that the differences observed were the result of
diabetes status rather than an effect of obesity. When age was
stratified by diabetes status, no differences in antibody responses
were observed among those diabetic patients older than 40 years
of age and those younger than 40 years of age. However, in those
without diabetes, we observed a significant association between
age and low antibody titers in individuals older than 40 years of
age. These results suggested that the lower titers observed in par-
ticipants with diabetes were not affected by older age. When BMI
was stratified by diabetes status, there was no significant difference
in IgG titer among diabetics with BMI values of greater than or less
than 30 (P  0.91 and 0.08, respectively).
The unadjusted odds ratio for diabetes status showed that par-
ticipants without diabetes had 2.19 (95% CI, 1.47 to 3.25) times
the odds of having a positive IgG response compared to partici-





(n  429) P valuee
No. (%) male 34.9 (46) 34.0 (146) 0.86
Age (yr) 59.5 (49.0–67.0) 45.0 (32.0–58.0) 0.001***
BMI (kg/m2) 32.2 (28.8–36.1) 29.9 (26.0–33.1) 0.001***
FBG concn (mmol/liter) 144.0 (115.0–202.0) 96.0 (91.0–103.0) 0.001***
% A1c 8.0 (6.7–10.3) 5.9 (5.3–6.5) 0.001***
CRP concn (mg/liter)a 4.6 (2.2–7.7) 3.3 (1.9–6.0) 0.01*
Albumin concn (g/dl)b 3.7 (3.6–4.0) 3.8 (3.7–4.0) 0.06
HDL concn (mg/dl) 44.0 (36.5–50.5) 48.0 (42.0–55.0) 0.001***
LDL concn (mg/dl)c 98.0 (77.0–121.0) 100.5 (80.4–121.0) 0.56
Triglyceride concn (mg/dl)d 167.5 (111.0–251.0) 123.5 (82.0–186.5) 0.001***
a n  557.
b n  159.
c LDL, low-density lipoprotein (n  555).
d n  554.
e *, P  0.01; **, P  0.001; ***, P  0.001. P values represent the difference in the median values, presented as medians (IQ range) for continuous variables and median
percentages (IQ range) for categorical variables.
FIG 1 Comparison of anti-PspA titers between individuals with and individuals without diabetes. Titers of PspA (A) and Efb (B) were measured in a standard
ELISA as described in Materials and Methods. Significantly higher titers of antibodies to both PspA and Efb were observed in no-diabetes control participants
than participants with diabetes. Each point represents a single plasma sample tested in duplicate. A P value of 0.05 was considered significant. NDM,
participants without diabetes mellitus; DM, participants with diabetes mellitus.
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pants with diabetes (Table 4). However, adjusting for age and BMI
attenuated this association, rendering it statistically nonsignifi-
cant (OR, 1.40; 95% CI, 0.91 to 2.15). For each year of increase in
age, the odds of having a positive IgG response decreased by 0.96
(95% CI, 0.95 to 0.97), and this association remained after adjust-
ing for diabetes status and BMI (OR, 0.96; 95% CI, 0.95 to 0.97).
For each kg/m2 of increase in BMI, the odds of having a positive
IgG response decreased by 0.98 (95% CI, 0.96 to 1.010); however,
this association was not statistically significant for either adjusted
or unadjusted odds ratios.
To determine if participants with diabetes on hypoglycemia
medication have a better response to PspA than diabetics on no
medication, we compared the median titers between those that
were taking medication and those that were not taking any med-
ication. Our results indicated that participants on medication for
diabetes had significantly lower antibody titers than individuals
not on medication (P  0.01) (Table 5). However, there was a
significant difference in the trend of the median anti-PspA IgG
titers when comparing all three categories (individuals on one
medication, individuals on more than one medication, and ones
taking no medication) (P  0.01). No significant difference in
median anti-PspA IgG titers was observed when individuals tak-
ing 1 diabetes medication and individuals taking 2 medications
were compared (Table 5).
Poorly controlled diabetes was negatively associated with
antibody titers. It has been shown that individuals with poorly
controlled diabetes are at a higher risk of invasive pneumococcal
infections than individuals with well-controlled diabetes (42, 45).
To determine if this difference might be associated with any of the
measures of diabetes control, we evaluated the association of FBG
and A1c with titers of antibodies in our total sample. We observed
a moderate negative association of both FBG (r  0.13, P 
TABLE 2 Participants positive for IgG antibodies to PspA
Antibodya







PspA 43.2 (57) 63.5 (268) 0.0001b
PRRc 47.37 (9) 48.51 (65) 0.93
a Titers of antibodies to the full-length 30-kDa fragment of PspA were measured.
b P  0.01, representing differences in percent positive.
c For PRR analysis, a subset of 134 samples was utilized to determine the specificity of
IgG to the PRR of PspA.
TABLE 3 Association of diabetes with anti-PspA titer with adjustment
for age and BMIa






Stratification of diabetes status by age
and BMI
Participants aged 40 yr
Diabetes 174.5 (105.0–227.6) 0.02*
Nondiabetes 197.6 (134.3–260.6)
Participants ages 40 yr
Diabetes 259.5 (172.5–263.3) 0.12
Nondiabetes 276.0 (192.0–329.5)
Participants with BMIs of 30 kg/m2
Diabetes 175.9 (112.5–228.8) 0.003**
Nondiabetes 218.3 (147.0–287.3)
Participants with BMIs of 30 kg/m2
Diabetes 182.3 (102.4–255.8) 0.002**
Nondiabetes 227.5 (165.8–298.1)
Stratification of age and BMI by
diabetes status
Participants with diabetes
Age  40 yr 174.5 (105.0–277.6) 0.09
Age  40 yr 259.5 (172.5–263.3)
Participants without diabetes
Age  40 yr 197.6 (134.3–260.6) 0.001***
Age  40 yr 276.0 (192.0–329.3)
Participants with diabetes
BMI  30 kg/m2 175.9 (112.5–228.8) 0.85
BMI  30 kg/m2 182.3 (102.4–255.8)
Participants without diabetes
BMI  30 kg/m2 218.3 (147.0–287.3) 0.10
BMI  30 kg/m2 227.3 (165.8–298.1)
a Comparisons were made between participants with and participants without diabetes
after controlling for age and BMI.
b *, P  0.01; **, P  0.001; ***, P  0.001. P values represent differences in the
medians.
TABLE 4 ORs and adjusted ORs comparing participants with positive
and negative IgG titers
Variable OR (95% CI) Adjusted ORa (95% CI)
Diabetes status 2.19 (1.47, 3.25)b 1.40 (0.91, 2.15)
Age (yr) 0.96 (0.95, 0.97)b 0.96 (0.95, 0.97)b
BMI (kg/m2) 0.98 (0.96, 1.01) 0.99 (0.97, 1.02)
a For adjusted OR, all variables were included in the logistic model.
b P  0.01.
TABLE 5 Association of diabetes medication with anti-PspA titer for all




concn (ng/ml) P value
Comparison of participants with and
participants without diabetes
medication
All participants (n  561)
No diabetes medication 223.5 (156.9–292.1) 0.001a
Diabetes medication 164.3 (94.5–219.8)
Participants with diabetes (n  132)
No diabetes medication 207.0 (149.3–282.6) 0.004b
Diabetes medication 164.3 (94.5–219.8)
Comparison of participants with
diabetes on and not on diabetes
medication
Participants with diabetes
No diabetes medication (n  43) 207.0 (149.3–282.6) 0.01c
1 diabetes medication (n  69) 164.3 (99.5–221.3)
2 diabetes medications (n  20) 174.4 (70.8–218.3)
Participants with diabetes on
medication
1 Diabetes medication (n  43) 164.3 (94.5–219.8) 0.58
2 Diabetes medications (n  20) 174.4 (70.8–218.3)
a P  0.001, representing the difference in the medians.
b P  0.001, representing the difference in the medians.
c P  0.01, by analysis of variance, representing the difference in the medians.
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0.01; Fig. 1A and 2A) and HbA1c (r  0.1, P  0.1; Fig. 1B and
2B) with IgG titers. The optimum antibody response was observed
at FBG values of 100 to 150 mg/dl and A1c values of 5 to 7 mg/dl.
The association of BMI with IgG titers was moderately statistically
significant (Fig. 2C).
Plasma specimens from participants with diabetes deposited
less complement on pneumococci than samples from nondia-
betic participants. Pneumococcal surface proteins such as PspA
and PspC and pneumococcal capsular polysaccharide prevent de-
position and activation of complement on the surface of pneumo-
cocci. An important function of antibodies during pneumococcal
infections is therefore the enhancement of complement deposi-
tion and subsequent phagocytosis of the bacterium. We therefore
measured the ability of our plasma specimens to deposit comple-
ment. We incubated pneumococci in the presence and absence of
heat-inactivated human plasma and measured the deposition of
baby rabbit complement in a fluorescence-activated cell sorter
(FACS) assay. A significant difference in antibody-mediated en-
hancement of complement deposition was observed between in-
dividuals with and individuals without diabetes (Fig. 3) (P 
0.04). Plasma specimens from nondiabetic individuals showed a
measurable increase in fluorescence intensity (2-fold), indicating
a strong opsonic activity of antibodies. However, only a marginal
increase (1- to 1.5-fold) in complement deposition was observed
when plasma specimens from diabetic participants were used to
measure complement deposition.
To determine the avidity of antibodies, we measured deposi-
tion of complement using 1% and 10% human plasma. A signif-
icant increase in deposition of complement was observed at both
concentrations when plasma samples from the control group
FIG 2 Association of antibody (Aby) titer with FBG concentration, A1c concentration, and BMI. The association between variables was calculated using the
Spearmen rank test. FBG and A1c values were found to be negatively associated with antibody titers. A P value of 0.05 was considered significant.
FIG 3 Complement deposition using plasma samples from diabetes and no-
diabetes controls. Capsule type 2 strain D39 was incubated in the presence or
absence of plasma from participants. Enhancement in deposition of baby rab-
bit complement was measured as the fold increase in mean fluorescent inten-
sity (MFI) of bacteria in the presence of plasma from participants. Each point
represents a single plasma sample run in duplicate. Fold increase was calcu-
lated by dividing the mean fluorescent intensity of pneumococci incubated
with plasma by the mean fluorescent intensity of pneumococci incubated
without plasma. The two groups were compared using a nonparametric t test
for comparison of means. A P value of 0.05 was considered significant.
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without diabetes were used, indicating a high avidity of the anti-
bodies. Comparable complement deposition occurred at 10%
plasma from diabetes participants, which was decreased by 5-fold
when plasma was used at a final concentration of 1% (data not
shown).
We investigated the association of diabetes-related variables,
particularly antibody titer, FBG concentration, and A1c concen-
tration, with complement deposition. A moderately positive asso-
ciation was observed between complement deposition and anti-
PspA titer (Fig. 4A). A moderate negative association between fold
increases in complement deposition and FBG concentration was
observed (r  0.2, P  0.09); however, the association was not
statistically significant (Fig. 4B). A statistically significant associa-
tion between fold increases in complement deposition and A1c
concentration was observed (r  0.3, P  0.02) (Fig. 4C). These
results suggested that the opsonic ability of antibodies was altered
in individuals with poorly controlled diabetes.
Higher titers of antibodies and respective titers of opsonic
activity to capsular type 14 in participants with diabetes than
those without diabetes. Titers of antibodies to eight different cap-
sular polysaccharides were measured in selected plasma samples
as described in the Materials and Methods section (Fig. 5). Among
all serotypes tested, titers to serotype 19F were highest among the
eight serotypes tested. When geometric means for titers were com-
pared between those with and those without diabetes, we observed
a significantly higher titer against serotype 14 among participants
with diabetes (P  0.01) than controls without diabetes. Although
not statistically significant, titers of antibodies to capsular types
19V and 18C were also higher in participants with diabetes. Addi-
tionally, titers against the most commonly occurring serotype
(6B) were relatively higher in participants without diabetes than
the diabetes group.
FIG 4 Correlation of complement deposition with anti-PspA, FBG, and A1c concentrations. The fold increase in complement deposition was correlated with
variables associated with diabetes. A strong positive association of antibody concentration with an increase in the mean fluorescent intensity was observed,
whereas moderate negative associations between an increase in mean fluorescent intensity and the AIc concentration and an increase in the mean fluorescent
intensity and the FBG concentration were observed. Each point represents a plasma sample run in duplicate. Correlations were calculated using a nonparametric
Spearman correlation test. A P value of 0.05 was considered significant.
FIG 5 Titers of antibodies to capsular polysaccharide in individuals with di-
abetes and no-diabetes controls. Concentrations of antibodies to eight differ-
ent capsular polysaccharides were measured using a WHO ELISA. Each bar
represents the geometric mean concentration (in g/ml). Comparison be-
tween individuals with diabetes and no-diabetes controls was performed using
a nonparametric test. A P value of 0.05 was considered significant.
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To further analyze the functionality of antibodies, we per-
formed opsonophagocytosis assays using the neutrophil-like cell
line HL-60 and baby rabbit complement. Heat-inactivated plasma
specimens were incubated with target strains of pneumococci,
followed by addition of baby rabbit complement, and then incu-
bated with HL-60 cells. The higher titers of antibodies against
capsule type 14 strains observed also corresponded with demon-
stration of higher opsonic activity (Table 6). That is, the opsonic
titer (the highest titer of plasma at which 50% killing is observed)
of plasma from diabetic participants was 2,016, whereas it was 649
for participants without diabetes (P  0.05). We observed a strong
negative association of titers with A1c and FBG levels.
DISCUSSION
It is well-known that protection against carriage and invasive
pneumococcal infection depends on the generation of protective
titers of antibodies against both pneumococcal capsular polysac-
charide and protein antigens (29, 32, 39). Protective antibodies are
defined as antibodies that can efficiently opsonize pneumococci
and induce phagocytic killing by resident macrophages or neutro-
phils (41). To determine if the susceptibility of individuals with
diabetes is the result of lower titers or a poor protective ability of
generated antibodies to capsular polysaccharide and/or protein
antigens, we measured both titers and protective antibody func-
tions. Our observation that diabetes was associated with poor an-
tibody responses to PspA was consistent with observations made
by Nam et al. indicating that baseline positive rates of cross-reac-
tive antibodies against pandemic influenza virus in patients with
diabetes were lower than those in age- and sex-matched nondia-
betes controls (35). Additionally, Fabrizi et al. reported a lower
seroprotection rate elicited by the hepatitis B vaccine in diabetics
(both influenza virus and hepatitis B virus are protein antigens)
(13).
Several factors can contribute to the observed poor antibody
responses to protein antigens in individuals with diabetes, such as
(i) alterations in antigen presentation, (ii) impairment in anti-
body generation, and (iii) antibody modification as a result of
hyperglycemia. There is strong evidence for the perturbation of
functions of sentinel cells such as monocytes/macrophages, neu-
trophils, antigen-presenting B cells, dendritic cells, and natural
killer cells. Any or all of these defects can compromise the anti-
body responses to protein antigens. Additionally, B-cell immuno-
globulin production is also altered in diabetes. This impairment in
antibody generation is attributed to diabetes-mediated hypergly-
cemia. It has been shown that even in the absence of other com-
ponents of the metabolic syndrome, hyperglycemia can temporar-
ily alter the B-cell response. Using a mouse model, it was
demonstrated that stimulation of total spleen cells from Akita
mice (a model for hyperglycemia due to insulin misfolding)
resulted in delayed immunoglobulin  production (36). Addi-
tionally, a variety of abnormalities in T-cell functions have been
reported in individuals with diabetes (with or without poor met-
abolic control). These abnormalities have been shown to be asso-
ciated with impairment in the ability to produce circulating B cells
and specific IgM and IgG antibody in response to vaccines.
Consistent with these observations, we also observed a negative
association of antibody titer with FBG and A1c, indicating a role
for hyperglycemia in the B-cell-mediated antibody response.




IgG concn (g/ml) Opsonic titer Antibody potencyd
GMCa 95% CI P value GMTb 95% CI P value GMPc 95% CI P value
4 Diabetes 0.36 0.19–0.66 0.42 95.6 18.6–493.0 0.60 195.4 38.9–982.0 0.14
No diabetes 0.25 0.18–0.35 240.3 67.3–858.5 971.3 315.0–2,995.0
6B Diabetes 1.29 0.68–2.45 0.57 847.1 250.1–2,868.8 0.93 371.4 90.6–1,523.0 0.82
No diabetes 1.06 0.73–1.53 941.1 253.9–3,489.1 363.6 83.5–1,584.6
9V Diabetes 0.88 0.49–1.58 0.16 764.5 149.0–3,923.6 0.28 419.6 82.1–2,144.2 0.54
No diabetes 0.60 0.45–0.80 570.6 225.2–1,445.8 955.4 469.0–1,946.1
14 Diabetes 3.60 1.71–7.61 0.03e 2,016.1 840.1–4,838.1 0.05e 487.1 165.8–1,431.1 0.84
No diabetes 1.46 0.81–2.63 649.5 224.4–1,879.9 385.5 101.6–1,462.2
18C Diabetes 1.13 0.51–2.53 0.57 168.6 40.4–704.3 0.32 116.4 35.4–382.6 0.61
No diabetes 0.95 0.63–1.45 43.6 6.8–280.6 52.1 11.6–234.8
19A Diabetes 1.47 0.85–2.56 0.99 543.8 142.8–2,071.1 0.37 195.3 46.8–815.4 0.71
No diabetes 1.38 0.95–2.02 193.9 42.5–884.7 136.0 33.4–553.5
19F Diabetes 2.26 1.36–3.78 0.40 68.9 13.6–349.7 0.88 27.9 5.3–145.7 0.32
No diabetes 2.63 1.91–3.62 55.1 16.3–186.3 13.4 5.8–31.1
23F Diabetes 0.84 0.32–2.17 0.70 134.3 22.1–816.6 0.66 168.2 15.2–1,864.2 0.60
No diabetes 0.53 0.36–0.78 235.5 45.1–1,230.7 450.0 55.3–3,664.3
a GMC, geometric mean concentration.
b GMT, geometric mean titer.
c GMP, geometric mean potency.
d Antibody potency was calculated as opsonic titer/IgG concentration.
e P  0.01, representing the difference in the geometric mean values.
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Moreover, the low opsonic titers observed in our studies could
also be explained by hyperglycemia. Accumulation of glucose in
individuals with poorly controlled diabetes results in nonenzy-
matic glycation and subsequent loss of antibody function. Mass
spectrometric analysis of immunoglobulins isolated from the
plasma of diabetics showed an increase in the molecular weight of
immunoglobulins. The weight increase corresponded with the
number of glucose molecules deposited on the protein. The non-
enzymatic glycation of immunoglobulins as a result of hypergly-
cemia could result in low antigen and receptor binding capacities
of these antibodies. It is therefore likely that despite comparable
titers, the functionality of the antibody is compromised in diabet-
ics compared to nondiabetics (25, 26).
Contrary to our findings with PspA, we observed comparable
titers of antibodies to all eight capsular polysaccharides tested in
individuals with and individuals without diabetes. These findings
were consistent with previous studies where comparable pre- and
postimmunization titers of antibodies to capsular polysaccharides
were observed in individuals with and individuals without diabe-
tes. Additionally, diabetes patients also developed a similar mag-
nitude of responses to a pneumococcal vaccine as those without
diabetes. Similarly, patients with cystic fibrosis have similar titers
of anticapsular antibodies (24), suggesting that responses to cap-
sular polysaccharide are least affected by disorders that affect the
immune system in general. Although titers to all serotypes were
comparable between individuals with and individuals without di-
abetes, we observed a significantly higher titer to capsule type 14 in
individuals with diabetes. Serotype 14 is mainly associated with
bacteremia in elderly individuals. Older age (59 versus 45 years;
P  0.01), and the higher susceptibility of diabetes individuals to
invasive bacteremic pneumonia might explain the higher titer to
serotype 14 in diabetics. In a study conducted by Schenkein et al.,
higher titers of capsular type 14 as a result of vaccinations were
observed in older individuals than younger adults. Despite higher
titers, a low opsonic activity was observed in these individuals
(41), which is contrary to our observations demonstrating that
higher antibody titers corresponded to higher opsonic activity. A
simple explanation for these results is that even though the anti-
bodies used in these assays were from individuals with or individ-
uals without diabetes, the complement and granulocytes were not.
Knowing that protection is the cumulative effect of the three com-
ponents, namely, neutrophils, complement, and antibodies,
working in a synergy, it is difficult to interpret this response as a
protective response. It is very likely that even though the antibod-
ies had a high opsonic activity, complement or the neutrophils
from individuals with diabetes have impaired function, resulting
in failure to protect against infections.
Results from our studies suggested that the response to protein
antigens was compromised in individuals with diabetes. The T
cells play a significant role in response to protein antigens by ac-
tivating B cells and initiating antibody class switching. We have
therefore focused our future studies on understanding the effect of
diabetes on T-cell function and differentiation. Our working hy-
pothesis is that diabetes creates an environment that modulates
the differentiation and functions of T-cell subsets. Current studies
are devoted to measuring the kinetics and strength of the T-cell
response to heat-killed S. pneumoniae in whole blood of partici-
pants with and participants without diabetes. More specifically,
we are measuring the differentiation of T cells into their subsets
after antigenic stimuli. Future studies will involve vaccinating our
participants and measuring the T-cell response to pneumococcal
vaccines (polysaccharide and conjugate) in whole blood of indi-
viduals with and individuals without diabetes. These studies will
provide us with an in-depth understanding of mechanisms that
lead to vaccine failure in individuals with diabetes.
Limitations to this study are that it was performed in a pre-
dominantly Hispanic population, making it difficult to generalize
our results to individuals of other ethnicities. Elucidating the
mechanism resulting in low antibody titers with opsonic potential
will also be difficult since these studies were carried out in vitro. A
mouse model of diabetes or obesity will be important to the rep-
lication of these studies for understanding the mechanisms asso-
ciated with failure to respond to protein antigens.
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